bayer roundup

A judge has reduced a $2 billion jury verdict in a Roundup lawsuit to $86 million. The California judge said the $2 billion award was excessive and unconstitutional, but denied Bayer’s appeal to eliminate the damages completely. The company said it will continue to appeal the decision. (Reuters)

Documents from a congressional investigation have exposed details of Juul’s youth and influencer programs. The e-cigarette maker developed curriculum to use in schools, summer camps and after-school programs. It also ran an influencer campaign to “seed” Juul products. (MM&M)

The Food and Drug Administration has added a black box warning to Pfizer’s Xeljanz. The warning tells patients that they could experience a higher risk of blood clots or death with a specific dose of the drug that treats rheumatoid arthritis and psoriatic arthritis. (MarketWatch)

AbbVie beat expectations in its Q2 earnings. The company touted sales of its newest drug, Skyrizi, which treats psoriasis. After just two months on the market, Skyrizi earned $48 million in sales, while Humira sales continued to drop. (BioPharma Dive)

The first cannabidiol drug has moved another step closer to approval in Europe. GW Pharma’s Epidiolex received a positive opinion from the European Medicines Agency. The company is expecting the agency to make a final decision within two months. The drug has been approved in the U.S. (MarketWatch)